immunology
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
October 3, 2025Medical Communications, Research and Development Dermatology, Immunology, acute urticaria, chronic spontaneous urticaria, dermatology, immunology
The current forms of immunotherapy, how T cell therapy works and what the future holds
Brian Adams appointed as Kymera’s CLO and Corporate Secretary
September 11, 2025Kymera, biopharma, corporate, immunology
Brian Adams has been appointed as Kymera Therapeutics’ Chief Legal Officer (CLO) and Corporate Secretary. He will lead Kymera’s legal, …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
August 3, 2025Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
Richard Philipson appointed as chief medical officer of Hansa Biopharma
July 9, 2025Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology
Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
May 14, 2025Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
Hansa Biopharma appoints Renée Aguiar-Lucander as CEO
April 24, 2025Research and Development CEO, Corporate, Hansa Biopharma, appointment, immunology
Swedish biopharma company, Hansa Biopharma, has announced the appointment of new chief executive officer (CEO) Renée Aguiar-Lucander, replacing Søren Tulstrup …
Shane Olwill appointed as chief development officer at Asgard Therapeutics
March 28, 2025Business Services, Clinical Research Asgard Therapeutics, CDO, Oncology, appointment, immunology
Asgard Therapeutics has announced the appointment of Shane Olwill as chief development officer (CDO). The biotech company develops in vivo …
BioGen to acquire Human Immunology Biosciences for $1.15bn
May 23, 2024Business Services Biogen, HI-Bio, Immunology, acquisition, immunology
BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire …
AbbVie and Tentarix collaborate on oncology and immunology treatments
February 23, 2024Research and Development AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
Gilead and Compugen enter exclusive license agreement for immunotherapy programme
December 20, 2023Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …
AstraZeneca to acquire Icosavax for up to $1.1bn
December 12, 2023Business Services AstraZeneca, Icosavax, Immunology, acquisition, immunology, vaccines
AstraZeneca has announced that it has entered into a definitive agreement to acquire Icosavax for approximately $15 per share or …
Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial
August 10, 2023Research and Development Cancer Research UK, Oncology, Sosei Heptares, clinical trial, immunology
Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed in their phase 1/2a clinical …
Eli Lilly to acquire DICE Therapeutics for immunology innovations
June 21, 2023Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology
Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …
Latest content
FibroFind appoints Lee Borthwick as CEO
